Search

Displaying results 6691 - 6700 of 10000 in total
  1. Drug

    Fucoxanthin

    go.drugbank.com/drugs/DB15462
    Investigational

    In vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. … Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).

  2. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause

  3. Drug

    SR 121463

    go.drugbank.com/drugs/DB05455
    Investigational

    It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).

  4. Drug

    Londamocitinib

    go.drugbank.com/drugs/DB19190
    Investigational

    Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high

    Synonyms: (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, 1-piperazineacetamide, n-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.-(methoxymethyl)-4-methyl-, (.alpha.r)-
  5. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. … Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  6. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    Preclinical characterization reports that RGN6024 binds the colchicine-binding site of beta-tubulin, inhibits microtubule polymerization in biochemical and cellular assays, induces G2/M arrest in glioblastoma … Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug.

  7. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in … RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.

  8. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    HbF production in erythrocytes (RBC). … SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.

  9. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).

  10. Drug

    Vintafolide

    go.drugbank.com/drugs/DB05168
    Investigational

    Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.